Alendronic Acid
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Alendronic Acid
Alendronic Acid: Known uses and market status in Australia
Summary
All of the TxGNN deep-learning model’s candidates for Alendronic Acid (score ≥ 0.99) that can be traced to a source are already known uses, so there is currently no new predicted indication. The one known use among the candidates is a relation recorded in the knowledge graph, not an approval found in a licence or label. This page lists those known uses and the market status in Australia.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| bone Paget disease |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 13499L | APO-Alendronate | Tablet 70 mg (as alendronate sodium) | Valid |
Safety Considerations
- Knowledge-graph contraindication signals (from drug–disease contraindication links, not product label text):
- Oesophageal conditions: achalasia, megaoesophagus, oesophageal dysmotility, oesophageal ulcer, oesophagitis (including eosinophilic and peptic), gastro-oesophageal reflux disease
- Other gastrointestinal conditions: gastritis, duodenitis
- Renal and mineral conditions: kidney disease, nephrolithiasis, nephrocalcinosis, hypercalcaemia, hyperphosphataemia, phosphorus metabolism disease
- Bone and vitamin D conditions: osteomalacia, rickets, vitamin D deficiency, hypervitaminosis
- Other: osteonecrosis of the jaw, atrial fibrillation, sarcoidosis, arteriosclerosis obliterans
- Drug Interactions (100 interactions recorded; examples listed):
- Moderate: calcium salts (acetate, carbonate, citrate, gluconate, lactate, phosphate), magnesium salts, aluminium hydroxide, iron, kaolin, attapulgite, magaldrate, acetylsalicylic acid, kanamycin
- Minor: famotidine, ranitidine, cimetidine
Many of the moderate interactions involve products that reduce oral absorption of bisphosphonates. Please refer to the TGA-approved Product Information (PI) for authoritative warnings, contraindications and dosing advice.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.